Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Malignant Lymphoma

  Free Subscription


11.02.2019

1 Am J Hematol
4 Blood
16 Br J Haematol
1 Cancer
2 Haematologica
1 Int J Cancer
3 J Clin Oncol
6 Leuk Lymphoma
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Hematol

  1. ARORA N, Eule C, Gupta A, Li HC, et al
    Clinicopathologic Features, Management and Outcomes of Plasmablastic Lymphoma: A Ten-Year Experience.
    Am J Hematol. 2019 Feb 7. doi: 10.1002/ajh.25432.
    PubMed     Text format    


    Blood


  2. Ren W, Ye X, Su H, et al. Genetic landscape of hepatitis B virus-associated diffuse large B-cell lymphoma. Blood. 2018;131(24):2670-2681.
    Blood. 2019;133:620.
    PubMed     Text format    

  3. HSI ED, Li H, Nixon AB, Schoder H, et al
    Serum levels of TARC, MDC, IL10 and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study.
    Blood. 2019 Feb 5. pii: blood-2018-08-870915. doi: 10.1182/blood-2018-08-870915.
    PubMed     Text format     Abstract available

  4. LYAPICHEV KA, You MJ
    Unusual presentation of classic Hodgkin lymphoma.
    Blood. 2019;133:502.
    PubMed     Text format    

  5. GREEN DJ, O'Steen S, Lin Y, Comstock ML, et al
    CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies.
    Blood. 2018;131:611-620.
    PubMed     Text format     Abstract available


    Br J Haematol

  6. GALANINA N, Smith SM, Liao C, Petrich A, et al
    University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL.
    Br J Haematol. 2018;181:264-267.
    PubMed     Text format    

  7. GIFFORD G, Gabrielli S, Gill A, Greenwood M, et al
    Lymphoma cell-of-origin assignment by gene expression profiling is clinically meaningful across broad laboratory contexts.
    Br J Haematol. 2018;181:272-275.
    PubMed     Text format    

  8. MESGUICH C, Cazeau AL, Bouabdallah K, Hindie E, et al
    Hodgkin lymphoma: is there really a need for interim and end-of-treatment FDG-PET evaluations? - Response to Adams & Kwee.
    Br J Haematol. 2018;181:124-125.
    PubMed     Text format    

  9. ADAMS HJA, Kwee TC
    Hodgkin lymphoma: is there really a need for interim and end-of-treatment FDG-PET evaluations?
    Br J Haematol. 2018;181:122-123.
    PubMed     Text format    

  10. RESTELLI V, Vagni M, Arribas AJ, Bertoni F, et al
    Inhibition of CHK1 and WEE1 as a new therapeutic approach in diffuse large B cell lymphomas with MYC deregulation.
    Br J Haematol. 2018;181:129-133.
    PubMed     Text format    

  11. MENTER T, Medani H, Olavarria E, Kanfer E, et al
    Pathology findings in patients with cutaneous T-cell lymphomas treated with allogeneic haematopoietic stem cell transplantation.
    Br J Haematol. 2018;180:904-908.
    PubMed     Text format    

  12. ALLEN PB, Pavone ME, Smith KN, Kazer RR, et al
    The impact of fertility preservation on treatment delay and progression-free survival in women with lymphoma: a single-centre experience.
    Br J Haematol. 2018;180:901-904.
    PubMed     Text format    

  13. SINGAVI AK, Shah NN
    Graft-versus-host disease-associated hepatic portal venous gas.
    Br J Haematol. 2018;181:9.
    PubMed     Text format    

  14. STASILOJC G, Felberg A, Okroj M
    Parameters critical for the effector mechanism of anti-CD20 antibodies revisited.
    Br J Haematol. 2018;180:777-779.
    PubMed     Text format    

  15. CAIRO MS, Beishuizen A
    Childhood, adolescent and young adult non-Hodgkin lymphoma: current perspectives.
    Br J Haematol. 2019 Feb 6. doi: 10.1111/bjh.15764.
    PubMed     Text format     Abstract available

  16. ZANELLI M, Zizzo M, De Marco L, Bisagni A, et al
    Fibrin-associated diffuse large B-cell lymphoma.
    Br J Haematol. 2019 Feb 6. doi: 10.1111/bjh.15786.
    PubMed     Text format    

  17. METZGER ML, Mauz-Korholz C
    Epidemiology, outcome, targeted agents and immunotherapy in adolescent and young adult non-Hodgkin and Hodgkin lymphoma.
    Br J Haematol. 2019 Feb 6. doi: 10.1111/bjh.15789.
    PubMed     Text format     Abstract available

  18. ROSENBAUM CA, Jung SH, Pitcher B, Bartlett NL, et al
    Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance).
    Br J Haematol. 2019 Feb 5. doi: 10.1111/bjh.15768.
    PubMed     Text format     Abstract available

  19. VU K, Mannis G, Hwang J, Geng H, et al
    Low-dose lenalidomide maintenance after induction therapy in older patients with primary central nervous system lymphoma.
    Br J Haematol. 2019 Feb 3. doi: 10.1111/bjh.15787.
    PubMed     Text format    

  20. EHRHARDT MJ, Hochberg J, Bjornard KL, Brinkman TM, et al
    Long-term survivors of childhood, adolescent and young adult non-Hodgkin lymphoma.
    Br J Haematol. 2019 Feb 3. doi: 10.1111/bjh.15775.
    PubMed     Text format     Abstract available

  21. DANIEL V, Delamain MT, Murbach BA, de Souza CA, et al
    Role for DNA base-excision repair gene variants in the prognosis of Hodgkin lymphoma.
    Br J Haematol. 2019 Jan 31. doi: 10.1111/bjh.15779.
    PubMed     Text format    


    Cancer

  22. CAGLAYAN C, Goldstein JS, Ayer T, Rai A, et al
    A population-based multistate model for diffuse large B-cell lymphoma-specific mortality in older patients.
    Cancer. 2019 Feb 1. doi: 10.1002/cncr.31981.
    PubMed     Text format     Abstract available


    Haematologica

  23. HICKS SW, Tarantelli C, Wilhem A, Gaudio E, et al
    The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity than SAR3419 in CD19-positive lymphoma and leukemia models.
    Haematologica. 2019 Feb 7. pii: haematol.2018.211011.
    PubMed     Text format     Abstract available

  24. GONZALEZ-FARRE B, Ramis-Zaldivar JE, Salmeron-Villalobos J, Balague O, et al
    Burkitt-like lymphoma with 11q aberration: A germinal center derived lymphoma genetically unrelated to Burkitt lymphoma.
    Haematologica. 2019 Feb 7. pii: haematol.2018.207928.
    PubMed     Text format     Abstract available


    Int J Cancer

  25. MPUNGA T, Znaor A, Uwizeye FR, Uwase A, et al
    A case-control study of HIV infection and cancer in the era of antiretroviral therapy in Rwanda.
    Int J Cancer. 2018 Apr 16. doi: 10.1002/ijc.31537.
    PubMed     Text format     Abstract available


    J Clin Oncol

  26. SORIGUE M, Sancho JM
    Is Longer Progression-Free Survival a Goal Worth Pursuing in Follicular Lymphoma?
    J Clin Oncol. 2019 Feb 8:JCO1801761. doi: 10.1200/JCO.18.01761.
    PubMed     Text format    

  27. BICCLER JL, Glimelius I, Eloranta S, Smeland KB, et al
    Relapse Risk and Loss of Lifetime After Modern Combined Modality Treatment of Young Patients With Hodgkin Lymphoma: A Nordic Lymphoma Epidemiology Group Study.
    J Clin Oncol. 2019 Feb 6:JCO1801652. doi: 10.1200/JCO.18.01652.
    PubMed     Text format     Abstract available

  28. O'CONNOR OA, Ozcan M, Jacobsen ED, Roncero JM, et al
    Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma.
    J Clin Oncol. 2019 Feb 1:JCO1800899. doi: 10.1200/JCO.18.00899.
    PubMed     Text format     Abstract available


    Leuk Lymphoma

  29. ZHANG C, Amos Burke GA
    Pediatric precursor B-cell acute lymphoblastic leukemia with MYC 8q24 translocation - how to treat?
    Leuk Lymphoma. 2017 Oct 12:1-7. doi: 10.1080/10428194.2017.1387914.
    PubMed     Text format     Abstract available

  30. ROBERTS ZJ, Better M, Bot A, Roberts MR, et al
    Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.
    Leuk Lymphoma. 2018;59:1785-1796.
    PubMed     Text format     Abstract available

  31. LEPIK KV, Mikhailova NB, Moiseev IS, Kondakova EV, et al
    Nivolumab for the treatment of relapsed and refractory classical Hodgkin lymphoma after ASCT and in ASCT-naive patients.
    Leuk Lymphoma. 2019 Feb 4:1-4. doi: 10.1080/10428194.2019.1573368.
    PubMed     Text format    

  32. OKA S, Ono K, Nohgawa M
    Successful treatment with mogamulizumab of refractory/relapsed angioimmunoblastic T-cell lymphoma following autologous stem cell transplantation.
    Leuk Lymphoma. 2019 Feb 8:1-3. doi: 10.1080/10428194.2018.1537489.
    PubMed     Text format    

  33. PHILIP J, Collins A, Ritchie D, Le B, et al
    Patterns of end-of-life hospital care for patients with non-Hodgkin lymphoma: exploring the landscape.
    Leuk Lymphoma. 2019 Feb 7:1-9. doi: 10.1080/10428194.2018.1564047.
    PubMed     Text format     Abstract available

  34. MARTIN P
    The optimal chemotherapy regimen for primary mediastinal B-cell lymphoma: we may never know.
    Leuk Lymphoma. 2019 Feb 8:1-2. doi: 10.1080/10428194.2018.1535119.
    PubMed     Text format    


    PLoS One

  35. TOLEDANO MN, Vera P, Tilly H, Jardin F, et al
    Comparison of therapeutic evaluation criteria in FDG-PET/CT in patients with diffuse large-cell B-cell lymphoma: Prognostic impact of tumor/liver ratio.
    PLoS One. 2019;14:e0211649.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: